- Kindeva has appointed David Stevens as Chief Executive Officer, effective 1 January 2026, following a planned leadership transition.
- Outgoing CEO Milton Boyer will continue to serve as an independent member of the Board of Directors.
Kindeva has announced a series of planned leadership transitions aimed at supporting growth across its parenteral and inhaled drug delivery businesses. The changes are part of a succession plan initiated in October 2025.
Effective 1 January 2026, David Stevens, previously President at Kindeva, has assumed the role of Chief Executive Officer. The company stated that the appointment is intended to support continued innovation, capacity expansion and customer partnerships within its core contract manufacturing and drug delivery activities.
As part of the transition, Milton Boyer has stepped down as Chief Executive Officer and will remain with the company as an independent member of the Board of Directors. Kindeva said this move is designed to provide continuity and ongoing strategic guidance.
“I am deeply honored to have the opportunity to succeed Milton as Kindeva’s Chief Executive Officer and look forward to building on his success.The company’s focus will remain on growth, performance and the delivery of drug delivery solutions for customers.”
David Stevens
George Aitken-Davies, co-founder and Managing Director at Altaris, said that the leadership changes position Kindeva to execute its strategy and deliver value for customers, employees and stakeholders, while recognising Milton Boyer’s contributions and continued involvement at board level.
